What is the half-life of Precedex (dexmedetomidine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Precedex (Dexmedetomidine) Half-Life

The elimination half-life of dexmedetomidine is approximately 2 hours (specifically 1.8-3.1 hours) in patients with normal liver function. 1

Specific Half-Life Values

  • The terminal elimination half-life ranges from 83-159 minutes (approximately 1.4-2.7 hours) in patients with normal hepatic function 1
  • A simplified half-life of 2 hours is commonly cited in clinical guidelines 2
  • Research studies have reported an elimination half-life of 3.7 hours (geometric mean) in critically ill patients receiving prolonged infusions 3

Factors That Prolong Half-Life

  • Elderly patients have decreased clearance and prolonged elimination half-life 4
  • Hypoalbuminemia increases the volume of distribution at steady state and prolongs the context-sensitive half-time 4
  • Severe hepatic dysfunction significantly impairs clearance, requiring lower doses due to prolonged drug elimination 1, 5
  • Decreased cardiac output reduces dexmedetomidine clearance, leading to higher plasma concentrations 4

Context-Sensitive Half-Time Considerations

  • For prolonged infusions (>24 hours), the context-sensitive half-time becomes more clinically relevant than the terminal elimination half-life 1
  • The context-sensitive half-time is particularly important in elderly patients and those with hypoalbuminemia, where drug accumulation may occur during extended use 4

Clinical Implications

  • Despite the relatively short half-life, dexmedetomidine demonstrates linear pharmacokinetics up to doses of 2.5 μg/kg/hour, even with prolonged infusions lasting up to 14 days 3
  • The drug's inactive metabolite (H-3) has a longer half-life of 9.1 hours, though this metabolite is practically inactive and does not contribute to clinical effects 3
  • No withdrawal effects (including rebound tachycardia or hypertension) have been reported upon discontinuation, even after prolonged use beyond 24 hours 6

References

Guideline

Dexmedetomidine Dosage and Role in ICU Sedation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Dexmedetomidine in Neurosurgical Cases

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prolonged infusions of dexmedetomidine in critically ill patients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.